DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
OMCL logo

Omnicell, Inc. Stock Price

NasdaqGS:OMCL Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

OMCL Share Price Performance

US$32.25
-1.03 (-3.09%)
​
US$61.29
Fair Value
US$32.25
-1.03 (-3.09%)
47.4% undervalued intrinsic discount
US$61.29
Fair Value
Price US$32.25
AnalystConsensusTarget US$61.29
AnalystLowTarget US$45.00
AnalystHighTarget US$70.00
Thu, 4 Jun 26
Fair ValueUS$61.29
Share Pricen/a

OMCL Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$61.29 47.4% undervalued intrinsic discount

OmniSphere Adoption Will Simplify Healthcare Medication Management

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$45 28.3% undervalued intrinsic discount

Government Cost Containment And Cybersecurity Burdens Will Impair Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$70 53.9% undervalued intrinsic discount

Aging Population And Digital Transformation Will Drive Medication Automation

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
OMCL logo
Omnicell
28.3% undervalued intrinsic discount

Government Cost Containment And Cybersecurity Burdens Will Impair Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 14 Aug
Read Narrative
OMCL logo
Omnicell
53.9% undervalued intrinsic discount

Aging Population And Digital Transformation Will Drive Medication Automation

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Jul
Read Narrative
OMCL logo
Omnicell
47.4% undervalued intrinsic discount

OmniSphere Adoption Will Simplify Healthcare Medication Management

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
OMCL logo

OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple

Fair Value: US$45 28.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
OMCL logo

OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes

Fair Value: US$70 53.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
OMCL logo

OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand

Fair Value: US$61.29 47.4% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
4 Rewards
View Full Analysis

Omnicell, Inc. Key Details

US$1.2b

Revenue

US$698.0m

Cost of Revenue

US$548.7m

Gross Profit

US$509.6m

Other Expenses

US$39.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.86
44.01%
3.13%
13.0%
View Full Analysis

About OMCL

Founded
1992
Employees
3485
CEO
Randall Lipps
WebsiteView website
www.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Recent OMCL News & Updates

Seeking Alpha • Aug 25

Omnicell: Offers Good Value, But Uncertainty Remains

Summary Omnicell, which is down by -24% on a YTD basis, has also underperformed other medtech and small-cap healthcare stocks by a large margin. OMCL faces near-term headwinds, with YoY revenue contraction for the first time in seven quarters and increased uncertainty around product bookings for FY26. OMCL's sales cycle for its new-gen Titan XT system remains slow amid heightened competition and a lack of alacrity to upgrade from  old-gen systems. Gross margins in H2 are going to be pressured by memory chip shortages, leading to higher sourcing costs and a projected 50 bps margin hit in FY26. However, the weakness in the stock price has also made the stock emerge as one of the strong value bets within the small-cap healthcare universe. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 14

OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple

Analysts have trimmed their Omnicell price targets to a range centered around $45, citing a shift to a $45 fair value estimate from $50, even as they highlight strong recent results and note that the company’s pipeline and aging installed base could support bookings over time. Analyst Commentary on Omnicell Recent research commentary on Omnicell points to a mixed picture.

Recent updates

No updates

Omnicell, Inc. Competitors

HQY logo

HealthEquity

Symbol: NasdaqGS:HQY
Market cap: US$7.7b
HNGE logo

Hinge Health

Symbol: NYSE:HNGE
Market cap: US$7.4b
PACS logo

PACS Group

Symbol: NYSE:PACS
Market cap: US$7.1b
CHE logo

Chemed

Symbol: NYSE:CHE
Market cap: US$6.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide